Vistagen Therapeutics (VTGN) Financial Statements & Analysis

Vistagen Therapeutics (VTGN) Income Statement

Vistagen Therapeutics reported revenue of $1.27M in fiscal 2026 (fiscal year ended Mar 31, 2026), up 161.1% from $486.00K a year earlier. Vistagen Therapeutics posted a net loss of $69.69M, compared with a net loss of $51.42M a year earlier. Gross margin was 100.0% and operating margin -5683.7%. In the most recent quarter, Q1 fiscal 2027 (ended Jun 30, 2026), revenue was $1.48M, up 504.9% from the same quarter a year earlier.

Vistagen Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Vistagen Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Revenue & Gross Profit
Revenue	1.27	0.49	1.06	-0.23	1.11	1.09	0.00	0.00	0.00	1.25
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.09	0.08	0.00
Gross Profit	1.27	0.49	1.06	-0.23	1.11	1.09	-0.10	0.00	0.00	1.25
Operating Expenses
Research & Development	54.97	39.38	20.02	44.38	35.41	11.93	13.33	17.10	7.76	5.20
Selling, General & Administrative	18.42	17.08	14.06	14.66	13.25	7.10	6.55	7.43	6.44	5.87
Operating Expenses	73.40	56.46	34.09	59.04	48.89	19.02	19.87	24.53	14.20	11.50
Operating Income	-72.13	-55.97	-33.02	-59.27	-47.78	-17.93	-19.97	-24.56	-14.20	-10.25
Other Income/Expense
Interest Income	2.44	4.56	3.35	0.05	0.02	0.00	0.05	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.02	0.00	-0.01	0.02	0.01	0.01	0.01
Other Income/Expense	0.01	4.56	3.66	0.03	0.02	0.00	-0.80	-0.03	-0.14	0.00
Income
Income Before Tax	-69.68	-51.41	-29.36	-59.24	-47.76	-17.93	-20.77	-24.59	-14.34	-10.25
Income Tax Expense	0.01	-0.01	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-69.69	-51.42	-29.36	-59.25	-47.76	-42.32	-20.77	-24.59	-14.35	-10.26
Net Income - Continuous Operations	-69.69	-51.42	-29.36	-59.25	-47.76	-17.93	-20.77	-24.59	-14.35	-10.26
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-	-
EBITDA	-71.39	-55.82	-28.79	-58.74	-47.05	-17.82	-20.65	-24.47	-14.25	-9.77
EBIT	-72.13	-55.97	-33.02	-59.27	-47.78	-17.93	-	-	-	-
Depreciation & Amortization	0.73	0.15	0.57	0.53	0.71	0.12	0.10	0.09	0.08	0.05
Earnings Per Share
Basic EPS	-2.00	-2.00	-2.00	-9.00	-7.00	-15.00	-14.00	-26.00	-31.00	-41.00
Diluted EPS	-2.00	-2.00	-2.00	-9.00	-7.00	-15.00	-14.00	-26.00	-31.00	-41.00
Basic Shares Outstanding	38.07	30.88	19.35	6.96	6.60	2.87	1.46	0.95	0.46	0.25
Diluted Shares Outstanding	38.07	30.88	19.35	6.96	6.60	2.87	1.46	0.95	0.46	0.25

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Vistagen Therapeutics Financial Statements

What was Vistagen Therapeutics's revenue in fiscal 2026?

Vistagen Therapeutics reported revenue of $1.27M in fiscal 2026 (fiscal year ended Mar 31, 2026). That was up 161.1% from $486.00K a year earlier.

Is Vistagen Therapeutics profitable?

No. Vistagen Therapeutics reported a net loss of $69.69M in fiscal 2026. In fiscal 2025 it lost $51.42M.

What is Vistagen Therapeutics's operating margin?

Vistagen Therapeutics's operating income was −$72.13M on revenue of $1.27M in fiscal 2026, an operating margin of -5683.7%, compared with -11517.1% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition